FDA Clearance, Management Changes, and Clinical Study Updates - Research Report on Illumina, Array, Oncolytics, Intrexon, and

   FDA Clearance, Management Changes, and Clinical Study Updates - Research
         Report on Illumina, Array, Oncolytics, Intrexon, and STERIS

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 26, 2013

NEW YORK, November 26, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Illumina,
Inc. (NASDAQ: ILMN), Array BioPharma Inc. (NASDAQ: ARRY), Oncolytics Biotech,
Inc. (NASDAQ: INCY), Intrexon Corporation (NYSE: XON), and STERIS Corporation
(NYSE: STE). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Illumina, Inc. Research Report

On November 19, 2013, Illumina, Inc. (Illumina) announced that it has received
premarket clearance from the US FDA for the MiSeqDx system, the first
high-throughput DNA sequencing analyzer to receive FDA clearance. In addition,
the Company also reported that it has received FDA premarket clearance for
MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical
Sequencing Assay, and MiSeqDx Universal Kit. "Illumina is proud to be the
first company to obtain FDA clearance for a high-throughput DNA sequencing
analyzer and next-generation sequencing-based assays," said Greg Heath, Senior
Vice President and General Manager of Illumina's Diagnostics business. "With
the FDA clearance of the MiSeqDx, Illumina is providing clinicians and
clinical laboratories with the tools needed to obtain comprehensive and
reliable results from a DNA sequencing analyzer and enabling them to create
and deploy NGS-based molecular diagnostic tests for cystic fibrosis and a
wide-range of other applications." The Full Research Report on Illumina, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3cf2_ILMN

--

Array BioPharma Inc. Research Report

On November 21, 2013, Array BioPharma Inc. (Array) announced that Kevin Koch,
Ph.D., its President and Chief Scientific Officer, will be leaving the Company
to pursue other opportunities. "The board and executive team thank Dr. Koch
for his leadership and contributions to the success of Array over the past 15
years. During this time, Array advanced 19 novel compounds into clinical
trials, of which 14 remain in active development," said Ron Squarer, CEO of
Array. "With several of these programs in late stage trials, and a strong
management team in place, Array is well-positioned for continued success." The
Full Research Report on Array BioPharma Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/e048_ARRY

--

Oncolytics Biotech, Inc. Research Report

On November 21, 2013, Oncolytics Biotech, Inc. (Oncolytics) announced positive
top-line data for the endpoints in its double blinded, randomized clinical
study that examined REOLYSIN in combination with carboplatin and paclitaxel in
patients with second-line platinum-refractory, taxane-naïve head and neck
cancers. "The overall goal of this clinical trial was to determine the
specific parameters for the use of REOLYSIN in a registration study in head
and neck cancers," said Dr. Brad Thompson, President and CEO of Oncolytics.
"We are excited to move forward with our head and neck program, and intend to
discuss the design and execution of a follow-on registration study with
regulators in the near future." The Full Research Report on Oncolytics
Biotech, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0c64_ONCY

--

Intrexon Corporation Research Report

On November 18, 2013, Intrexon Corporation (Intrexon) announced the
appointments of Peter Seufer-Wasserthal, Ph.D., and Dana Di Ferdinando to the
positions of Vice President of Business Development for Europe and Asia, and
Chief Information Officer, respectively, effective immediately. "We are
excited to have Ms. Di Ferdinando and Dr. Seufer-Wasserthal join Intrexon at
this stage of our growth. Dana will lead development of the next generation of
Intrexon's proprietary technologies, particularly UltraVector®, an
industry-leading software platform that enables our collaborators to design,
test, and produce complex biological solutions with the goal of generating
superior commercial products. Peter will expand Intrexon's presence even
further into Europe and Asia, growing our international relationships to
establish additional collaborations abroad. I am confident that their
respective professional experiences and insights will be a tremendous asset to
Intrexon," said Krish Krishnan, Chief Operating Officer of Intrexon. The Full
Research Report on Intrexon Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/cb5c_XON

--

STERIS Corporation Research Report

On October 30, 2013, STERIS Corporation (STERIS) reported Q2 FY 2014 financial
results (period ended September 30, 2013). In Q2 FY 2014, the Company achieved
net revenues of $383.8 million, up 7.7% YoY. Q2 FY 2014 net income was $29.7
million, or $0.50 per diluted share, compared with net income of $40.1
million, or $0.68 per diluted share, in Q2 FY 2013. "We are pleased that our
performance returned to expectations this quarter, reflecting the continued
growth in our end-markets and success with new products," said Walt
Rosebrough, President and CEO of STERIS. "With solid organic growth across all
segments and strong backlog, we have confidence in our ability to produce a
strong second half of the year. Due largely to the timing of investments for
our in-sourcing projects, we now anticipate that earnings will be in the lower
half of our previously provided range of $2.47 to $2.60 for the full fiscal
year." The Full Research Report on STERIS Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/8e31_STE

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.